BillionToOne (BLLN) vs Caris Life Sciences (CAI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Caris Life Sciences is the larger company by market cap ($7.77 billion vs $4.50 billion), about 1.7 times the size, while BillionToOne is growing revenue faster (+100.0% vs +97.0%). On valuation, BillionToOne trades at a lower forward P/E (64.2x vs 74.7x for Caris Life Sciences). BillionToOne converts more of its revenue into profit, with a net margin of 2.4% versus -8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLLN | CAI |
|---|---|---|
| Share price | $95.41 | $27.50 |
| Market cap | $4.50B | $7.77B |
| 1-day change | -0.36% | +1.48% |
| YTD return | +17.00% | +0.44% |
| 1-year return | — | -14.19% |
| P/E ratio (TTM) | 151.44 | 16.27 |
| Forward P/E | 64.25 | 74.69 |
| EPS (TTM) | $0.63 | $1.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $305.11M | $812.03M |
| Revenue growth (YoY) | +99.97% | +96.97% |
| Net income (latest FY) | $7.45M | $-68.09M |
| Gross margin | 68.32% | — |
| Operating margin | 5.25% | 5.56% |
| Net margin | 2.44% | -8.38% |
| 52-week high | $150.44 | $33.65 |
| 52-week low | $61.96 | $14.19 |
| Distance from 52-week high | -36.58% | -18.28% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +35.21% | +5.75% |
| Average volume | 696.43K | 4.93M |
| Shares outstanding | 42.64M | 282.68M |
| Employees | 713 | 1,846 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BillionToOne trades at a higher earnings multiple (151.4x vs 16.3x trailing P/E).
- BillionToOne is more profitable, keeping 2.4 cents of every revenue dollar as net income versus -8.4 cents for Caris Life Sciences.
About BillionToOne
BLLN stock →BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.
Health Care · Medical Specialities · 713 employees
About Caris Life Sciences
CAI stock →Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Health Care · Medical Specialities · 1,846 employees
BLLN vs CAI FAQ
Which is bigger, BillionToOne or Caris Life Sciences?
Caris Life Sciences (CAI) is larger, with a market capitalization of $7.77B compared with $4.50B for BillionToOne (BLLN).
Which has the lower P/E ratio, BLLN or CAI?
CAI has the lower trailing P/E at 16.3, versus 151.4 for BLLN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are BillionToOne and Caris Life Sciences in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.